Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Free Cash Flow (2017 - 2025)

Sutro Biopharma (STRO) has disclosed Free Cash Flow for 9 consecutive years, with -$24.9 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 65.75% to -$24.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$177.2 million through Dec 2025, up 8.94% year-over-year, with the annual reading at -$177.2 million for FY2025, 8.94% up from the prior year.
  • Free Cash Flow hit -$24.9 million in Q4 2025 for Sutro Biopharma, up from -$39.7 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $61.8 million in Q3 2022 to a low of -$72.8 million in Q4 2024.
  • Historically, Free Cash Flow has averaged -$29.5 million across 5 years, with a median of -$33.0 million in 2021.
  • Biggest five-year swings in Free Cash Flow: soared 428.8% in 2022 and later tumbled 1429.14% in 2023.
  • Year by year, Free Cash Flow stood at -$34.7 million in 2021, then rose by 21.61% to -$27.2 million in 2022, then skyrocketed by 146.38% to $12.6 million in 2023, then plummeted by 676.41% to -$72.8 million in 2024, then skyrocketed by 65.75% to -$24.9 million in 2025.
  • Business Quant data shows Free Cash Flow for STRO at -$24.9 million in Q4 2025, -$39.7 million in Q3 2025, and -$43.6 million in Q2 2025.